Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDose TR Phase 2b Study
NCT02754596Phase 2Completed
- Sponsor
- Glaukos Corporation
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Glaukos Corporation. Primary endpoint: Intraocular Pressure Change From Baseline at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02754596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754596.